Complete metabolic response in patients with advanced non-small cell lung cancer with prolonged response to immune checkpoint inhibitor therapy

INTRODUCTION: Immunotherapy is the new standard of care in advanced non-small cell lung cancer (NSCLC). Recently published data show that treatment discontinuation after 12 months of nivolumab treatment is associated with shorter survival. Therefore, the ideal duration of immunotherapy remains uncle...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:J Immunother Cancer
Main Authors: Ferdinandus, Justin, Metzenmacher, Martin, Kessler, Lukas, Umutlu, Lale, Aigner, Clemens, Kambartel, Karl-Otto, Grünwald, Viktor, Eberhardt, Wilfried Ernst Erich, Fendler, Wolfgang Peter, Herrmann, Ken, Faehling, Martin, Christoph, Daniel Christian
פורמט: Artigo
שפה:Inglês
יצא לאור: BMJ Publishing Group 2021
נושאים:
Clinical/Translational Cancer Immunotherapy
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC8016096/
https://ncbi.nlm.nih.gov/pubmed/33789880
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-002262
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים